New Science

A dynamic combination of the best in science and health technology is filling unmet needs with more precise and effective treatments.

Image Thumbnail

Go from billions to millions

Generating value through greater R&D productivity
READ MORE

Outcomes in New Science

Science isn’t just in petri dishes anymore. Novel technology is increasingly involved. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care.

Scientific innovation capabilities drive the biopharma sector both to develop treatments and manage global health. But science has changed—so how we innovate must also change. The way we measure benefits for patients and populations is going to shape the future.

In 2019, Accenture identified and defined New Science: a dynamic combination of the best in science and health technology that is driving more growth than originally predicted.

LEARN MORE

What is New Science?

New Science is Accenture’s global analysis of regulated scientific treatments in both the pipeline and the market. It classifies science using different dimensions to understand its dynamics for patients, companies and markets. The dimensions include:

Scientific novelty

Enables better understand of future areas of growth in disease and overall therapeutic areas, and better manage portfolio risk.

Unmet need

Measuring treatments that qualify as achieving current unmet need ensures development of medicines for patient impact.

Technology convergence

Measuring medicines that coexist with technology in the near-term and future ensures a better understanding of science’s growing dependence on tech.

View All
Image Thumbnail

Built for Change a podcast from Accenture

New Science-A new economic reality for growth
LISTEN NOW

Breathe new life into your work

Biopharma companies need a partner who understands how to combine technology and human ingenuity and work with you to “do the impossible”—provide better treatments in a more affordable, accessible way. We help do so across all areas of your business.

R&D transformation

Embracing digital to speed up drug discovery and development, improve pipeline productivity and provide a better clinical trial experience.

Commercial services

Modernizing your commercial model to align evidence and economics to outcomes, design experiences for impact and engage with customers differently.

Supply chain, manufacturing and quality

Creating a patient centric and intelligent supply chain that’s able to manufacture new and more complex products and innovative supplier partnerships.

Cloud

Finding new ways to unlock data, increase collaboration, create more meaningful engagement and transform your culture to embrace new ways of working.

View All
Research and development

New Science: A new economic reality for growth

A new economic environment is demanding change in biopharma—especially as New Science grows in prominence. New Science has the potential to make medicine vastly more precise and effective, but will its price tag keep it out of most people’s reach?

READ MORE
"The investment in scientific innovation is born by all stakeholders and felt most deeply by patients. Now the goal must be maximizing return on that investment for patients, too. There are better, faster ways to deliver innovation—2020 proved that."

— STUART HENDERSON, Global Lead – Accenture Life Sciences

Case studies

A biopharmaceutical company collaborates with Accenture to navigate a complex FDA submission for an innovative cell therapy.

Bristol Myers Squibb upgrades global SAP to S/4HANA in the AWS cloud flawlessly and without business disruption.

Public-private partnership model transforms primary care for Kenya’s citizens.

View All

Blogs

Digital Health: Put the care back in healthcare

Accenture's Ted Boyle explores how healthcare industries can put the care back in healthcare.

Weaving the digital thread for life sciences

The digital thread works to tackle the ongoing challenges within life sciences through greater connectivity & data visibility across the ecosystem.

Making the impossible possible: Galien Forum 2021

Accenture's Petra Jantzer co-moderated the Galien Golden Jubilee Forum and discussed critically important lessons learned from COVID-19.

Our leaders